Partial Edentulism in the Maxilla or in the Mandible
Conditions
Brief summary
The purpose of this study is to evaluate the outcome of implant OsseoSpeed EV compared to implant OsseoSpeed TX with regards to marginal bone level changes and implant survival rate up to five years after implant loading. The hypothesis is that there will be no clinically relevant differences in marginal bone level alterations one year after functional loading.
Interventions
DEVICEOsseoSpeed EV
OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
DEVICEOsseoSpeed TX
OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
Sponsors
Dentsply Sirona Implants and Consumables
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Provision of Informed Consent. 2. 18 -75 years at enrollment. 3. In need of implant(s) replacing missing tooth/teeth in the maxilla or in the mandible (no edentulous jaws). 4. History of edentulism in the planned implant area of at least 3 months (at Visit 2). 5. At least 4 months of healing after last grafting procedure in the planned implant area (at Visit 2). 6. Deemed by the investigator to be suitable for one stage surgery and be likely to present an initially stable implant situation i.e. have a bone height and bone width suitable for the chosen study implants. 7. Deemed by the investigator to be suitable for loading after 6-8 weeks. 8. Deemed by the investigator to have a functional opposing dentition at the time of loading the implants i.e. an even distribution of contacts between the teeth in the opposite jaw and the planned permanent crown/bridge.
Exclusion criteria
1. Unlikely to be able to comply with study procedures, as judged by the investigator. 2. Uncontrolled pathological processes in the oral cavity. 3. Untreated, uncontrolled caries and/or periodontal disease. 4. Known or suspected current malignancy. 5. History of radiation therapy in the head and neck region. 6. History of chemotherapy within 5 years prior to surgery. 7. Systemic or local disease or condition that would compromise post-operative healing and/or osseointegration, as deemed by the investigator. 8. Uncontrolled diabetes mellitus. 9. Corticosteroids or any other medication that would compromise post-operative healing and/or osseointegration. 10. Smoking more than 10 cigarettes per day. 11. Present alcohol and/or drug abuse. 12. Current need for bone grafting and/or augmentation in the planned implant area. Local, minor soft tissue grafting will be allowed. 13. Involvement in the planning and conduct of the study (applies to both Astra Tech staff and staff at the study site). 14. Previous enrollment in the present study. 15. Simultaneous participation in other clinical studies at enrollment (Visit 1) and during the subject's first year of this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Marginal Bone Level Change After 1 Year in Use. | Evaluated at implant loading and at the 1 year follow-up after implant loading. | Marginal bone level will be determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 1 year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline). Positive value = bone gain, Negative value = bone loss. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Marginal Bone Level Change After 5 Years in Use. | Evaluated from implant loading to the 5 years follow-up after implant loading. | Marginal bone level will be determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 5 years follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline). |
Countries
Belgium, Germany, Italy, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| OsseoSpeed EV OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm | 59 |
| OsseoSpeed TX OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm | 61 |
| Total | 120 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| 1 Year Follow-up to 5 Year Follow-up | Adverse Event | 2 | 2 |
| 1 Year Follow-up to 5 Year Follow-up | Lost to Follow-up | 10 | 13 |
| 1 Year Follow-up to 5 Year Follow-up | Withdrawal by Subject | 3 | 0 |
| Enrollment to 1 Year Follow-up | Adverse Event | 4 | 1 |
Baseline characteristics
| Characteristic | OsseoSpeed EV | OsseoSpeed TX | Total |
|---|---|---|---|
| Age, Continuous | 50 years STANDARD_DEVIATION 16 | 51 years STANDARD_DEVIATION 13 | 51 years STANDARD_DEVIATION 14 |
| Sex: Female, Male Female | 34 Participants | 29 Participants | 63 Participants |
| Sex: Female, Male Male | 25 Participants | 32 Participants | 57 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 0 / 59 | 0 / 61 |
| serious Total, serious adverse events | 13 / 59 | 13 / 61 |
Outcome results
Primary
Marginal Bone Level Change After 1 Year in Use.
Marginal bone level will be determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 1 year follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline). Positive value = bone gain, Negative value = bone loss.
Time frame: Evaluated at implant loading and at the 1 year follow-up after implant loading.
Population: In the EV group, 55 subjects (73 implants) completed the 1 year follow-up visit.~In the TX group, 60 subjects (84 implants) completed the 1 year follow-up visit. Three of the radiographs were not possible to evaluate, giving an overall number of 59 subjects (81 implants) as basis for the analysis of marginal bone level change.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| OsseoSpeed EV | Marginal Bone Level Change After 1 Year in Use. | 0.27 Millimeter | Standard Deviation 0.53 |
| OsseoSpeed TX | Marginal Bone Level Change After 1 Year in Use. | 0.14 Millimeter | Standard Deviation 0.47 |
Secondary
Marginal Bone Level Change After 5 Years in Use.
Marginal bone level will be determined from radiographs and expressed as the distance from a reference point on the implant to the most coronal bone-to-implant contact on the mesial and distal aspect of the implant. Marginal bone level expressed in millimeters at the 5 years follow-up visit compared to values obtained at delivery of permanent restoration i.e. loading (baseline).
Time frame: Evaluated from implant loading to the 5 years follow-up after implant loading.
Population: In the EV group, 40 subjects (52 implants) completed the 5-year follow-up visit.~In the TX group, 45 subjects (64 implants) completed the 5-year follow-up visit.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| OsseoSpeed EV | Marginal Bone Level Change After 5 Years in Use. | 0.24 Millimeter | Standard Deviation 0.85 |
| OsseoSpeed TX | Marginal Bone Level Change After 5 Years in Use. | 0.11 Millimeter | Standard Deviation 0.85 |